Business
Admission of New Shares
Admission of New Shares.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 2613U Allergy Therapeutics PLC 22 June 2009 \n \n\nMonday 22 June 2009\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n\nAdmission of New Shares Pursuant to Exercise of Options\n\nAllergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that is has applied for admission of 415,982 Ordinary Shares of 0.1 pence (\"Admission\") each pursuant to the exercise of options announced 12 June 2009. Admission is expected to be on or around Wednesday 24 June 2009.\n\nAfter Admission of the 415,982 shares, the issued share capital of the Company will be 82,366,614 Ordinary Shares.\n\nFor further information\n\n\n\n\n\nAllergy Therapeutics\n\n\n+44 (0) 1903 845 820\n\n\n\n\nKeith Carter, Chief Executive\n\n\n\n\n\n\n\nwww.allergytherapeutics.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNomura Code Securities\n\n\n+44 (0) 207 776 1200\n\n\n\n\nJuliet Thompson/ Clare Terlouw\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial Dynamics\n\n\n+44 (0) 207 831 3113\n\n\n\n\nBen Brewerton\n\n\n\n\n\n\n\n\n\n\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END LISSELSUESUSEDM\n ","length":3280,"tagName":"div"}]